<DOC>
	<DOCNO>NCT00784290</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Orantinib , oral tyrosine kinase inhibitor vascular endothelial growth factor receptor-2 , platelet-derived growth factor receptor , fibroblast growth factor receptor , patient advance hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Phase I/II Study TSU-68 Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>As HCC highly vascular tumor , number antiangiogenic agent test treatment HCC . Orantinib orally administer , small-molecule , multiple receptor tyrosine kinase inhibitor target vascular endothelial growth factor receptor-2 ( VEGFR-2 ) , platelet-derived growth factor receptor ( PDGFR ) , fibroblast growth factor receptor ( FGFR ) . Phase I study conduct Japan patient solid tumor recommend dosage 400 mg bid . As potent antiangiogenic agent , Orantinib also expect effective HCC . However , HCC patient accompany liver cirrhosis hepatitis , safety must reevaluate presence liver function impairment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Orantinib</mesh_term>
	<criteria>Age 2074 PS 02 Patients respond surgery , RFA , TAE , chemotherapy , radiotherapy ChidPugh A B At least one measurable lesion RECIST criterion Large amount pleural effusion ascites Esophageal varix Simultaneously active double cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>